Core Insights - NeoGenomics reported a total revenue of $188 million for Q3 2025, marking a 12% year-over-year increase, driven by strong clinical revenue growth of 18% [1][3][4] - The company reaffirmed its full-year guidance for revenue, net loss, and adjusted EBITDA, indicating confidence in its growth trajectory despite challenges in non-clinical revenue [1][9] Financial Performance - Clinical revenue grew by 18%, with Next-Generation Sequencing (NGS) revenue increasing by 24% year-over-year, now representing nearly one-third of clinical revenue [1][3][4] - Average revenue per clinical test rose by 3% to $476, reflecting a shift towards higher-value tests [4] - Consolidated gross profit for Q3 2025 was $80 million, a 7% increase compared to Q3 2024, with a gross profit margin of 43% [5][6] - Operating expenses increased by 12% to $107 million, primarily due to impairment charges and higher compensation costs [7][8] Loss and Adjusted Metrics - The net loss for Q3 2025 increased by 53% to $27 million compared to a net loss of $18 million in Q3 2024 [8] - Adjusted EBITDA was positive at $12 million, a decline of 9% from the previous year [5][8] - Adjusted net income was reported at $3.6 million, down from $6.9 million in Q3 2024 [8] Guidance and Future Outlook - The company reaffirmed its full-year 2025 guidance, projecting consolidated revenue between $720 million and $726 million, with a net loss expected between $108 million and $116 million [9][10] - NeoGenomics aims to leverage its oncology-centric test menu and strong customer focus to drive growth in clinical volumes, particularly in NGS testing [3][4]

Core Insights - Immutep Limited announced positive results from the EFTISARC-NEO Phase II trial, demonstrating significant efficacy of eftilagimod alfa (efti) in combination with radiotherapy and KEYTRUDA® for resectable soft tissue sarcoma (STS) [1][5] - The trial met its primary endpoint, achieving a median tumor hyalinization/fibrosis of 51.5%, significantly exceeding the prespecified target of 35% [1][5] - The results indicate a potential for improved overall survival and recurrence-free survival in STS patients, addressing a substantial unmet medical need in this area [2][5] Company Overview - Immutep is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 [7] - The company aims to provide innovative treatment options and maximize shareholder value through its diversified product portfolio [7] Clinical Trial Details - The EFTISARC-NEO Phase II trial was investigator-initiated and involved a diverse population of STS subtypes, showcasing a robust safety profile with minimal severe toxicity [1][2] - The study was primarily funded by a grant from the Polish government through the Polish Medical Research Agency program [2] Eftilagimod Alfa (Efti) Mechanism - Efti is an MHC Class II agonist that activates antigen-presenting cells, stimulating both adaptive and innate immune responses to combat cancer [4][6] - The therapy is under evaluation for various solid tumors, including non-small cell lung cancer and head and neck squamous cell carcinoma, with favorable safety allowing for multiple combination therapies [6]

Company Overview - NeoGenomics (NEO) shares increased by 6.3% to close at $9.97, with a notable trading volume compared to normal sessions, and a total gain of 17.4% over the past four weeks [1][2] Business Developments - The rise in share price is linked to positive investor expectations regarding the company's diagnostics business, particularly the upcoming presentation of new clinical data for the RaDaR ST molecular residual disease (MRD) assay at the ESMO 2025 medical conference [2] - The RaDaR ST assay is a personalized ctDNA test aimed at enhancing precision oncology and expediting drug development, positioning NeoGenomics as a key partner for biopharma companies [2] Financial Performance - NeoGenomics is projected to report quarterly earnings of $0.02 per share, reflecting a year-over-year decline of 60%, while revenues are expected to reach $183.63 million, marking a 9.4% increase from the previous year [3] - The consensus EPS estimate for the quarter has been revised 5.7% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] Industry Context - NeoGenomics operates within the Zacks Medical - Biomedical and Genetics industry, where Bristol Myers Squibb (BMY) also competes, having experienced a 0.4% decline in its last trading session and a -5.5% return over the past month [4] - Bristol Myers has a consensus EPS estimate of $1.56, which represents a 13.3% decrease from the previous year, and also holds a Zacks Rank of 3 (Hold) [5]

NORTHVILLE, Mich., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Tenneco proudly introduces GLYCODUR® NEO, its latest bearing solution featuring GLYCO 692, a groundbreaking, PFAS-free material engineered to meet the growing demand for sustainable, high-performance sliding solutions. Designed for both dry and lubricated use, GLYCODUR® NEO with GLYCO 692 sets a new benchmark in tribological performance, safety and versatility. “Our customers are seeking reliable, future-ready solutions that address both performance and ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, Oct. 28, 2025. ...

TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- 50 Metric Ton Multi-Year Offtake Supply Agreement of High-Performance Silicon Battery Material Technology with North American Lithium-Ion Battery CompanyTo Jointly Develop and Optimize Lithium-Ion & Lithium-Polymer Battery Products for Unmanned Systems, Drones, and Defense-Related Mobile Systems Targeting to Enhance Energy Density, Charging/Discharging Rate Capabilities with Safety, and High Power Output Active Progress on 20 TPA Production Scale-Up of Silicon Bat ...

TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost, silicon-enhanced battery developer that enables longer-running, rapid-charging batteries for drones, robotics, and electronics, is pleased to close its upsized non-brokered private placement (the “Offering”) through the issuance of 10,785,836 units (each, a “Unit”) at a price of $0.51 CAD per Unit for aggregate gross proceeds of approximately $5,500,000. Each Unit consists of ...

Core Insights - Alger Weatherbie Specialized Growth Fund's second-quarter 2025 investor letter highlights the impact of trade policy uncertainty on market volatility, particularly due to President Trump's tariffs, which affected import-dependent companies [1] - The S&P 500 reached a record high by the end of Q2 2025, with a gain of 10.94%, aided by improved market sentiment following the suspension of reciprocal tariff hikes on China [1] - Class A shares of the fund outperformed the Russell 2500 Growth Index during the same period [1] Company Analysis: NeoGenomics, Inc. - NeoGenomics, Inc. is identified as a leading provider of specialty oncology lab testing services, with a focus on serving hospitals, oncologists, and pathologists [3] - The stock of NeoGenomics experienced a one-month return of 14.83%, but it has lost 45.66% of its value over the past 52 weeks, closing at $8.13 per share with a market capitalization of $1.05 billion as of September 23, 2025 [2] - Despite a revenue shortfall attributed to weakness in non-clinical segments, NeoGenomics exceeded consensus estimates for EBITDA and reaffirmed its full-year 2025 organic revenue guidance, while slightly increasing total revenue guidance due to a recent acquisition [3]

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost, silicon-enhanced battery developer that enables longer-running, rapid-charging batteries for drones, robotics, and electronics, is pleased to announce that due to strong demand from institutional and strategic investors, the Company has upsized its previously announced non-brokered private placement (the “Offering”) for aggregate gross proceeds of $4,000,000 to approximately ...

Core Viewpoint - NeoGenomics (NEO) is currently in Phase 18 of its Adhishthana Cycle, indicating a prolonged period of consolidation with little sign of breakout until August 2026 [1][10]. Summary by Sections NEO's Cycle Overview - NEO has closely followed the Adhishthana Principles throughout its cycle, particularly between Phases 9 and 12, demonstrating a strong alignment with the model [2]. - Stocks in Phases 4 through 8 typically form a Cakra, which has bullish implications, leading to a breakout in Phase 9, marking the start of the Himalayan Formation [3]. Historical Performance - From May 2016 to September 2019, NEO traded within its Cakra, then broke out sharply in Phase 9, rising from $18 to $34 [5]. - The stock continued to rally in Phase 10, reaching a peak of $61, but subsequently began to decline, falling over 70% back to the breakout level near $18 [6]. Challenges Faced - The issues for NEO began upon entering the Guna Triads (Phases 14, 15, and 16), which are critical for determining the potential for achieving Nirvana in Phase 18 [7]. - For Nirvana to occur, the Guna Triads must exhibit Satoguna, indicating a sustainable bullish move, which NEO failed to demonstrate [8]. Current Status and Outlook - NEO remains in consolidation for over 850 days, with the current phase concluding in August 2026, suggesting continued stagnation [10]. - Investors are advised to be cautious, as the stock is unlikely to show significant movement in the near term, remaining "stuck in the Matrix" [11].